<DOC>
	<DOCNO>NCT00839397</DOCNO>
	<brief_summary>This 52-week , non-comparative , uncontrolled study paroxetine Japanese PTSD patient obtain clinical experience regard efficacy safety . In study , subject receive paroxetine 20mg-40mg daily even meal .</brief_summary>
	<brief_title>BRL29060A ( Paroxetine Hydrochloride Hydrate ) Posttraumatic Stress Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Patients primary diagnosis PTSD accord DSMIV criterion ( Posttraumatic Stress Disorder : 309.81 ) . In order diagnose PTSD , ClinicianAdministered PTSD ScaleDX Current Lifetime Diagnostic Version ( CAPSDX ) use . Disease Be Treated : Duration illness least 3 month Week 1 . Score &gt; = 50 Criteria B , C D CAPSSX . Age : &gt; =18 &lt; 65 year ( time acquisition inform consent ) Sex : No restriction Hospitalization Status : No restriction Informed consent : Gives his/her informed consent . In case subject age 20 , his/her parent/guardian must also give his/her write informed consent . Exclusion Criteria Week 1 Patients diagnosed Axis I disorder ( exclude PTSD ) major depression , dysthymia , simple phobia , OCD , panic disorder primary diagnosis accord DSMIV criterion within 24 week prior Week 1 . However , patient depressive disorder allow enroll study , PTSD present depressive disorder appear PTSD predominant disorder . Patients present current major depressive episode precede diagnosis PTSD . However , patient depressive disorder allow enroll study , PTSD present depressive disorder appear PTSD predominant disorder . Patients receive disability payment PTSD psychiatric disorder . Patients currently engage compensation litigation whereby personal gain would achieve prolonged symptom PTSD psychiatric disorder . Patients take St. Johns Wort . Patients meet DSMIV criterion substance abuse ( alcohol drug ) substance dependence within 24 week prior Week 1 . Patients attempt suicide within 24 week prior Week 1 pose , investigator 's judgement use M.I.N.I . `` C. Suicidality '' , high suicidal risk . Women pregnant lactating , may pregnant , plan pregnancy study . Patients take MAO inhibitor within 1 week prior Week 1 ( within 2 week prior Week 0 ) . Patients electroconvulsive therapy ( ECT ) within 12 week prior Week 1 . Patients treat another investigational drug within 12 week prior Week 1 . Patients history complication manic psychosis . Patients history complication convulsive disorder ( epilepsy , etc. ) . Patients complication glaucoma . Patients known tendency bleed predisposing condition . Patients history hypersensitivity paroxetine . Patients serious organic disorder brain . Patients serious physical symptom cardiac , hepatic , renal hematopoietic dysfunction . Patients history complication cancer malignant tumor . Others investigator subinvestigator considers ineligible study . Exclusion Criterion Week 0 Patients whose placebo runin medication compliance le 80 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>